[FDA Medical Device Newsletter] FDA Warning Regarding Risks of Using Unapproved Blood Pressure Measurement Devices
10/8/2025 (US FDA Published: September 16, 2025)
On September 16, 2025, the FDA issued a warning to consumers and healthcare professionals about unapproved medical devices claiming to measure blood pressure. Understanding whether medical devices are approved is crucial, as it directly affects both everyday health management and clinical decisions.
Key Points of This News:
Blood pressure is an essential indicator for assessing cardiovascular disease risk and determining treatment strategies. Decisions based on inaccurate blood pressure data can lead to serious health risks. According to the FDA, numerous unapproved blood pressure measurement devices are circulating in the market, presenting the following risks:
- • Misdiagnosis or delayed treatment due to incorrect readings
- • Failure to detect hypertension or hypotension
- • Increased clinical judgment errors by healthcare professionals
The FDA has issued this cautionary alert particularly because some devices readily available online or through retail channels have not undergone FDA safety and efficacy review.
FDA Recommendations
1. Use FDA-Approved Devices
Always select blood pressure measurement devices that have received FDA marketing authorization. Approved devices are guaranteed to meet standards for accuracy and safety.
2. Report Problems
If health harm or device malfunction occurs due to unapproved devices, reporting through the FDA's MedWatch system is recommended. This contributes to risk reduction for other consumers and healthcare settings.
Perspective from Medical Device Researchers
This warning highlights not only the risks of unapproved devices but also the importance of the approval process in medical device market entry.
- • Consumer products gain credibility by obtaining approval demonstrating "safety and accuracy."
- • For products intended for healthcare settings, the use of unapproved devices is directly linked to medical litigation risks.
- • Early FDA consultation (Pre-Submission) clarifies product development direction and market entry strategy.
At Globizz, we support medical device safety and market entry through the latest FDA application information and consulting services. We will continue to provide information useful for formulating product strategies based on the latest news.
